secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2026-09-11T21:00:52+00:00
Accession:  0001104659-26-107115
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

TransCode CFO Fitzgerald resigns; severance up to $1.25M, interim CFO Tattory appointed
--------------------------------------------------------------------------------

- Thomas A. Fitzgerald resigned as CFO, principal financial and accounting officer, and director effective Sept 9, 2026; no disagreement cited.
- Separation agreement includes $1,250,000 severance: $416,666.67 lump sum, $416,666.67 monthly over 12 months, $416,666.67 contingent on funding.
- Third payment accelerates 50% at $5M Qualified Funding, full at $10M; vesting of all outstanding equity awards accelerated, exercise period extended.
- New option granted for 185,000 shares at closing price on Sept 9, 2026, vesting monthly over 12 months with funding-based acceleration.
- John Tattory, 61, appointed interim CFO effective Sept 9, 2026, via Stout Risius Ross; has prior CFO roles at Windtree and Cerapedics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465926107115/0001104659-26-107115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465926107115/tm2625146d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-107115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer